INS and cardiovascular disorder: In conclusion, exenatide inhibits atherosclerotic progression to delay the development of cardiovascular disease in patients with T2DM compared to insulin therapy, in addition to its benefits of glucose-lowering, body weight control, and dyslipidemia improvement.